After APOLLO: Trevena Weighs Commercial Viability Of Opioid Oliceridine
A mixed bag of safety results for the new opioid Olinvo (oliceridine) in the Phase III APOLLO pain trials disappoints the market, but analysts are encouraged by the totality of the data and optimistic about approval.
You may also be interested in...
Oliceridine is not superior to morphine, has abuse potential similar to other mu opioid agonists, FDA concludes; also endpoint Trevena used to evaluate respiratory safety was inadequate, FDA says.
Also, TapImmune merger with Marker could yield T-cell therapies that address multiple tumor-associated antigens with a better safety profile than CAR-T therapy. Bluebird and Medigene expand their TCR therapy collaboration.
Keeping Track: New MCL Treatment Calquence, Submissions Galore, And A Breakthrough Designation For GSK
The latest drug development news and highlights from our US FDA Performance Tracker.